Introduction
The annual screening of women with mammography has contributed to the overall reduction in breast cancer mortality by increasing the early detection of clinically occult non-palpable breast tumors [1] . Depending upon a woman's ethnicity and breast tissue density, approximately 5 to 20 % of breast tumors evade mammographic detection and clinically present as a palpable mass or metastatic lesion [2, 3] .
Since the genetic and biochemical transformations occurring within a breast tumor ultimately construct the anatomic abnormalities perceived on mammography, molecular breast imaging (MBI) has gradually developed into a clinical tool capable of detecting aberrant metabolism within small malignant breast tumors [4] . The instrumentation of MBI, which includes positron emission mammography (PEM), single-photon mammography (SPM), and positron emission tomography/X-ray computed tomography (PET/CT), and the employment of these modalities in imaging the uptake of various metabolic tracers within breast tumors was recently reviewed [5, 6] .
As a supplemental screening exam, both PEM and SPM h a v e b e c o m e e f f e c t i v e t o o l s i n d i s c o v e r i n g mammographically and clinically occult non-palpable breast tumors in women with dense breast tissue [7] . If MBI is to ultimately function as a primary screening modality for pinpointing the early biochemical changes arising within an occult breast cancer, it must be paired with plasma and/or urine biomarkers indicating a metabolic pathway amenable to clinical imaging is aberrantly upregulated within a malignant breast tumor [8] .
The cobalamin (Cbl or vitamin B12) metabolic pathway was initially observed to be upregulated in mammary carcinomas shortly after the vitamin was discovered in 1948 [9] . Two of the proteins within the Cbl metabolic pathway were eventually found to be elevated in the serum of breast cancer patients [10, 11] . Cbl was ultimately discovered to have two co-enzymatic functions that uniquely support cellular proliferation. Within the cytoplasm, methylcobalamin (MC) is the co-enzyme for methionine synthase (MS). MS directly or indirectly supports cellular p r o d uc t i on o f m e t hi on i n e , t h y m i d i n e , a nd Sadenosylmethionine to sustain protein anabolism, DNA synthesis, and numerous methylation reactions, respectively. In the mitochondria, 5′-deoxyadenosylcobalamin (AC) is the co-enzyme for methylmalonyl CoA mutase (MMCM). MMCM represents the final step in the catabolism of branched chain amino acids, odd chain fatty acids, and cholesterol. The end product succinyl-CoA supports energy production (ATP) and tetrapyrrole ring synthesis.
The increased uptake of Cbl within rapidly proliferating cells was initially depicted diffusely throughout fetal murine tissue in utero and selectively in transplanted mammary tumors in adult mice by Co-57 labeled cyanocobalamin (CC) or [
57 Co]CC ( Fig. 1 ) and time-dependent autoradiography [12] . [ 57 Co]CC additionally assisted in deciphering that transcobalamin (TC) was the sole transport protein in serum to selectively bind and deliver Cbl to every tissue type in humans, that holo-TC (TC carrying a single molecule of Cbl) underwent endocytosis by the dedicated transcobalamin receptor (TC-R) expressed on all human cell membranes [13] , that holo-TC was primarily saturated with AC [14] , and that AC was the major co-enzymatic form of Cbl (50-70 %) in both normal and malignant human cells [15] .
The upregulated expression of TC-R on tumor cell membranes, in association with a greater cytoplasmic concentration of [ 57 Co]CC bound to TC during DNA replication, initially established that the TC:TC-R pathway was the primary mechanism responsible for Cbl endocytosis in malignant tissue [16] . To directly investigate Cbl uptake in tumors by the TC:TC-R pathway, we previously described the synthesis and radiolabeling of an AC analog [17] . In vitro we demonstrated that both TC and intrinsic factor (IF), the Cbl transport protein uniquely secreted by gastric parietal cells to capture newly ingested Cbl in the proximal small bowel and deliver it to the cubilinamnionless (CUBAM) receptors expressed in the terminal ileum, both selectively bound and transported [
111 In]AC. In vivo [
111 In]AC scintigraphically depicted the increased uptake of Cbl within transplanted human tumor xenografts in nude mice [17, 18] , in naturally occurring feline and canine tumors diagnosed by veterinarians [18, 19] and in a variety of clinically suspected malignancies in patients [20] [21] [22] .
Here [20, 21] .
Summarized within is the [
111
In]AC human and murine breast tumor imaging data, prior comparative investigations into Cbl uptake within normal and malignant breast tissue, and initial inquiry into potential genetic perturbations influencing the expression of the three Cbl transport proteins (transcobalamin, intrinsic factor, haptocorrin) and five Cbl receptor proteins (transcobalamin-R, megalin, cubilin, amnionless, asialoglycoprotein-R) within breast tumors. Normal tissue (brain, lung, heart, liver, spleen, left kidney, left quadriceps, left flank fat) and the MDA-MB-231 tumors were harvested and assayed for counts/min/mg tissue (CPM/ mg) after the completion of imaging on all DE and PC experiments as previously described [17] . 111 In]AC imaging data additionally indicates that the capacitance for Cbl uptake in malignant breast tumors and normal tissue is differentially robust. Specifically, the recommended daily allowance (RDA) for Cbl in humans and mice is 2.4 and 0.1 μg, respectively [25, 26] that the capacitance for Cbl uptake in her liver and foci of primary and metastatic breast tumor were not saturated. Correspondingly, neither the MDA-MB-231 tumors or murine kidneys, the primary site of Cbl storage in mice, were saturated by the large doses of AC or [
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Imaging Cbl Uptake within Patient Breast Tumors
111 In]AC.
Potential PC Mechanisms Impacting Cbl Uptake in Breast Tumors
A recent study observed that patients with chronic excess Cbl supplementation had the highest serum concentrations of holo-TC and sCD320 (the extracellular soluble component of TC-R). This subgroup of patients had Cbl serum levels greater than 1000 pmol/l [27] . It was posited that this subgroup of patients had developed an underlying increase in cellular metabolism and cell membrane TC-R activity that initiated an excess release of TC and sCD320 into the intravascular space. The hypothesis may partially explain the elevated Cbl serum concentrations and greater breast tumor Specifically, in mice subcutaneously administered 2.37 μg of CC/h for 4 weeks, a 50 % reduction in both TC and TC-R transcription, and Cbl concentration occurred in the lacrimal and salivary glands [28] . It is reasonable to posit that the chronic ingestion of Cbl reduced [
111 In]AC uptake in the majority of patient d/h normal tissue and contributed to increasing her [
111 In]AC T/B ratios and urinary excretion of tracer.
Precisely how a solitary bolus of AC or DEX enhanced [ 111 In]AC uptake in the MDA-MB-231 and patients breast tumors remains to be determined. Nevertheless, two prior human studies and the current murine 8 h PC data indicate that the TC:TC-R pathway was acutely upregulated. Specifically, in patients given a solitary I.V. bolus of 0.2 μg of CC/ kg, the mean TC serum concentration was suppressed by 53.5 % at 0.5 h post-injection, but gradually approached normal pre-injection levels by 8 h [29] .
Correspondingly, female patients administered a single intramuscular injection of 120 mg of DEX for two consecutive days had a mean 59 % increase in TC serum concentration [30] . These studies imply that a large bolus of Cbl or DEX acutely triggers a cellular or endovascular release of apo-TC. Given that the T 1/2 of TC-R renewal on cell membranes is 8 h, the murine 8 h PC data indicates that both a greater quantity of apo-TC in serum, and TC-R cell membrane expression augmented [
111 In]AC endocytosis in normal murine tissue and the MDA-MB-231 tumors.
Recently, a novel immunohistochemical staining assay demonstrated that TC-R was overexpressed in MDA-MB-231 tumors and that both TC-R and TC protein expression were markedly elevated in feline mammary carcinomas [31, 32] . The mean staining values for TC-R and TC in feline mammary tumors were 5263 and 5548, respectively, compared to 0.2 and 0.7 in normal peri-tumoral feline mammary tissue. The feline and MDA-MB-231 data Cbl cobalamin plasma concentration, TP true positive, TN true negative, FN false negative, T/B tumor to background ratio, NG nuclear grade, IG invasive grade, Breast tumor expression of ER estrogen receptor, PR progesterone receptor, HR human epidermal growth factor 2 receptor, Positive (+), Negative (−), Borderline (-), IDC intraductal carcinoma, DCIS ductal carcinoma in situ, DCA ductal cancer, LN axillary lymph node status for metastasis indicates that the TC:TC-R pathway was primarily responsible for Cbl endocytosis in human and feline mammary carcinomas.
Cbl Uptake in Breast Tumors Independent of the TC:TC-R Pathway
However, several murine and human studies have indicated that Cbl endocytosis within breast tumors can occur independent of the TC:TC-R pathway. For example, the Megalin (MEG) and CUBAM receptors have both been detected on human breast tumor cell membranes [33] . MEG is a crucial nutritional receptor that promotes cellular proliferation by facilitating the endocytosis of~50 substrates, including holo-TC, holo-IF, folate, vitamin D, lipoproteins, sterols, hormones, insulin, and sonic hedgehog [34] . MEG can function either independently or in combination with CUBAM when the two receptors are colocalized in tissue. Not surprisingly, MEG and CUBAM receptors are variably expressed throughout embryonic and fetal tissues during development. The importance of these receptors in supporting cellular proliferation was emphasized when antibodies directed against MEG and CUBAM, but not TC-R, caused fetal demise after their injection into pregnant mice [35] . Correspondingly, murine TC-R knock-out fetuses survived only until birth due to MEG maintaining maternofetal transport of Cbl in the visceral yolk sac and therefore Cbl uptake within fetal brain, spinal cord, and renal tissue in utero [36] .
In contrast, the expression of MEG and CUBAM receptors in adult humans is essentially limited to tissue barriers that capture and reclaim Cbl. Specifically, CUBAM within the terminal ileum, and MEG-CUBAM or MEG alone in the vascular barriers within the renal proximal tubule, lacrimal/salivary glands, and the choroid plexus. It will therefore be important to investigate if MEG or CUBAM receptor expression occurs on the cell membranes and/or neo-vascularity of breast tumors.
Recently, the increased intracellular concentration of haptocorrin (HC) was reported in multiple tumor cell lines, including within lobular, ductal, and mucinous breast tumor cells [37] . Waibel et al. postulated that an upregulation in the expression of the asialoglycoprotein receptor (ASGP-R), which is responsible for the endocytosis of holo-HC, was the mechanism to affect the increased concentration of HC in tumor cells. Although the overexpression of ASGP-R mRNA was observed in murine fetal and newborn tissues [38] , an assay to quantify ASGP-R expression on fetal or tumor cell membranes has yet to be reported.
To determine if the HC:ASGP-R pathway was more effective than the TC:TC-R pathway in imaging Cbl uptake in malignancies, Waibel et [40] . In the only breast cancer patient studied, the primary breast tumor had been resected prior to 
Cbl Transport and Receptor Proteins in Breast Cancer
The increased serum concentrations of HC and/or TC, reportedly observed in 50-65 % of breast cancer patients, were investigated as potential biomarkers. However, the reported variations in HC and TC expression within breast cancers only underscore the pleiotropic cytogenetic mechanisms remaining to be decrypted. Recently, several genetic aberrations supporting breast tumor growth were discovered to involve the cytogenetic bands encoding the Cbl transport/ receptor proteins.
The synthesis of TC in breast tumors was previously posited to be upregulated by ets transcription factors and a cmyc protein binding to specialized nucleic acid base motifs in the promoter region of the TC gene (TCN2) on chromosome 22q12.2 [43] . More recently, the amplification of the leukemia inhibitory factor (LIF) gene located on 22q.12.2 was discovered to promote the tumorigenesis and metastasis of breast cancer through the AKT-mTOR pathway [44] .
Correspondingly, human lactating breast tissue normally upregulates HC production~100-400 times to insure the delivery of Cbl to nursing newborns [45] . Although the cytogenetic mechanisms triggering the overexpression of HC in maternal lactating breast tissue and malignant breast tumor cells remain to be elucidated, the CTNND1 gene on 11q12.1, where HC (TCN1) and IF (GIF) genes are encoded, is frequently modified in biologically aggressive breast cancers [46] .
Finally, on the cytogenetic bands encoding the Cbl receptor protein genes: TC-R (CD320) on 19p13.2, MEG (LRP2) on 2q31.1, cubilin (CUBN) on 10p13, amnionless (AMN) on 14q32.32, and ASGP-R (ASGR1 and ASGR2) on 17p13.1, are foci of gene amplification or mutations that support breast tumor progression, for example, the amplification of DNMT1 on 19p13.2 [47] , PDK1 on 2q31.1 [48] , CAMK1D on 10p13 [49] , and AKT1 on 14q32.32 [50] and mutations of TP53 on 17p13.1 [51] . Intriguingly, with the concentration of sCD320 increasing in urine and serum during pregnancy, it suggests that the protein fragment may be a biomarker for cellular proliferation [52] .
Conclusion
The uptake of Cbl in malignant breast tumors can be clinically imaged and biochemically enhanced. Further investigation into targeting the Cbl metabolic pathway in breast tumors is warranted and could potentially uncover novel theragnostic targets. 
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